$24.82 Million in Sales Expected for Nektar Therapeutics (NKTR) This Quarter

Equities research analysts expect Nektar Therapeutics (NASDAQ:NKTR) to announce sales of $24.82 million for the current fiscal quarter, according to Zacks. Five analysts have made estimates for Nektar Therapeutics’ earnings. The lowest sales estimate is $20.08 million and the highest is $35.50 million. Nektar Therapeutics posted sales of $152.93 million during the same quarter last year, which would indicate a negative year over year growth rate of 83.8%. The business is scheduled to report its next earnings report on Tuesday, November 6th.

According to Zacks, analysts expect that Nektar Therapeutics will report full year sales of $1.18 billion for the current financial year, with estimates ranging from $1.17 billion to $1.20 billion. For the next fiscal year, analysts forecast that the firm will report sales of $457.12 million, with estimates ranging from $135.00 million to $1.18 billion. Zacks’ sales averages are an average based on a survey of research firms that cover Nektar Therapeutics.

Nektar Therapeutics (NASDAQ:NKTR) last posted its quarterly earnings data on Wednesday, August 8th. The biopharmaceutical company reported $5.33 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $5.22 by $0.11. Nektar Therapeutics had a net margin of 65.69% and a return on equity of 174.70%. The firm had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.03 billion. During the same quarter last year, the business posted ($0.39) EPS. The company’s revenue for the quarter was up 3043.7% on a year-over-year basis.

NKTR has been the subject of a number of research reports. ValuEngine raised shares of Nektar Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, August 28th. Piper Jaffray Companies set a $125.00 target price on shares of Nektar Therapeutics and gave the company a “buy” rating in a research report on Wednesday, July 25th. BidaskClub downgraded shares of Nektar Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, September 18th. Zacks Investment Research downgraded shares of Nektar Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday. Finally, William Blair reissued an “outperform” rating on shares of Nektar Therapeutics in a research report on Thursday, August 9th. Four research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $82.91.

Shares of Nektar Therapeutics stock traded up $1.01 on Wednesday, reaching $48.91. 2,001,546 shares of the company traded hands, compared to its average volume of 3,167,571. Nektar Therapeutics has a 52 week low of $22.75 and a 52 week high of $111.36. The company has a market capitalization of $10.51 billion, a P/E ratio of -88.93 and a beta of 2.39. The company has a quick ratio of 19.55, a current ratio of 19.67 and a debt-to-equity ratio of 0.13.

In related news, Director Jeffrey Robert Ajer sold 6,750 shares of the firm’s stock in a transaction that occurred on Thursday, September 20th. The shares were sold at an average price of $56.76, for a total value of $383,130.00. Following the completion of the transaction, the director now directly owns 15,750 shares of the company’s stock, valued at approximately $893,970. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Dennis L. Winger sold 30,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 21st. The stock was sold at an average price of $59.96, for a total transaction of $1,798,800.00. Following the completion of the transaction, the director now directly owns 57,750 shares of the company’s stock, valued at $3,462,690. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 96,000 shares of company stock valued at $5,825,680. 4.31% of the stock is owned by insiders.

A number of large investors have recently made changes to their positions in NKTR. Asset Management One Co. Ltd. purchased a new position in Nektar Therapeutics in the 1st quarter worth $110,000. We Are One Seven LLC purchased a new position in Nektar Therapeutics in the 1st quarter worth $118,000. Suntrust Banks Inc. purchased a new position in Nektar Therapeutics in the 1st quarter worth $264,000. Livforsakringsbolaget Skandia Omsesidigt purchased a new position in Nektar Therapeutics in the 2nd quarter worth $137,000. Finally, Flagship Harbor Advisors LLC purchased a new position in Nektar Therapeutics in the 2nd quarter worth $142,000. 92.20% of the stock is owned by hedge funds and other institutional investors.

About Nektar Therapeutics

Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.

See Also: How are the companies in the S&P 500 selected?

Get a free copy of the Zacks research report on Nektar Therapeutics (NKTR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply